AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
topiroxostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| xanthine oxydase and xanthine dehydrogenase inhibitor | 4888 | 577778-58-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
xanthine oxidoreductase inhibitor
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.742 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 6.310 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 51.761 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 10.568 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 20.260 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 26.320 | % | High | 1 |
| herg | hERG pIC50 | 4.179 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 8.851 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 8.241 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 12.330 | % | High | 1 |
| kinase-safety-class | ACVR1B,ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK19,CDK5,CDK9,CLK4,DDR1,DYRK1A,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK1,GRK2,GRK3,GSK3B,IRAK1,ITK,JAK1,KIT,MAP3K10,MAP3K21,MAP4K1,MAP4K3,MAPK7,MAPK9,MARK4,MTOR,PDK2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,TEK,TTK,ULK1 | 46 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,BRAF,CAMK2B,CAMK2D,CDK1,CDK9,DYRK1B,ERBB2,GRK2,IRAK1,MAPK7,SIK2,TNIK | 14 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 19.320 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 36.224 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 22.590 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 6.039 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 22.380 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 24.210 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 77.460 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 9.280 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 23.768 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 28, 2013 | PMDA | Senwa Kegaku Kenkyushp |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 47.65 | 38.76 | 15 | 282 | 89280 | 110499722 |
| Renal impairment | 40.18 | 38.76 | 16 | 281 | 188429 | 110400573 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D004791 | Enzyme Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperuricemia | indication | 35885006 | DOID:1920 |
| Gout | indication | 90560007 | DOID:13189 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.7 | acidic |
| pKa2 | 4.07 | Basic |
| pKa3 | 2.94 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Xanthine dehydrogenase/oxidase | Enzyme | INHIBITOR | IC50 | 8.28 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 6.75 | CHEMBL | |||||
| Xanthine dehydrogenase/oxidase | Enzyme | IC50 | 8.32 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 0J877412JV | UNII |
| D09786 | KEGG_DRUG |
| C4049065 | UMLSCUI |
| CHEMBL1078685 | ChEMBL_ID |
| 5288320 | PUBCHEM_CID |
| DB01685 | DRUGBANK_ID |
| 9220 | INN_ID |
| C504882 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10592 | IUPHAR_LIGAND_ID |
| CHEBI:42614 | CHEBI |
| FYX | PDB_CHEM_ID |
| 0J877412JV | INXIGHT DRUGS |
Pharmaceutical products:
None